Background: A phase II study was conducted in order to determine the toxicity and efficacy of the combination of CPT-11 and cisplatin, as salvage treatment in patients with advanced non-small-cell lung cancer (NSCLC), progressing after a docetaxel-based front-line regimen.
Introduction
Irinotecan (CPT-11), is a semi-synthetic derivative of the plant alkaloid, camptothecin. CPT-11 appears to exert its antineoplastic activity via inhibition of the nuclear enzyme topoisomerase I and recent studies have shown that the agent is active against NSCLC with objective responses ranging from 20%-47% [1] . An additive or synergistic effect for the combination of CPT-11 and cisplatin has also been described [2, 3] . Early phase I and II trials from Japan, demonstrated that the combination of CPT-11 and cisplatin is active in chemotherapynaive patients with NSCLC, achieving responses up to 50% [4, 5] . However, the optimal doses and administration schedules of CPT-11 in combination chemotherapy regimens have not been established [6] . The principal dose-limiting toxicities in all these studies have been delayed diarrhea and /or neutropenia, which are noncumulative, reversible and dose-related [1, 4, 5] .
In a recent phase I study we demonstrated that the maximum-tolerated dose of a CPT-11/cisplatin combination in patients with NSCLC, was CPT-11 100 mg/m 2 on day 1 and 110 mg/m 2 on day 8, and cisplatin 80 mg/m 2 on day 8 [7] . Therefore, we conducted a phase II trial with the same drug combination to further evaluate its role as second-line treatment in patients with metastatic NSCLC, previously treated with a docetaxel-based front-line regimen.
Patients and methods

Patient selection
Patients with histologically or cytologically confirmed NSCLC, bidimensionally measurable disease, aged < 75 years, who had failed frontline chemotherapy with docetaxel in combination with either gemcitabine (n = 23) or carboplatin (n = 8), were enrolled. Other eligibility criteria were: performance status (WHO) 0-2; a life expectancy of at least three months; inoperable stage IIIB or IV disease; adequate hematologic parameters (absolute granulocyte count > 1500/dl, hemoglobin level > 9 g/dl, and platelet count > 100,000/dl), adequate hepatic (serum bilirubin <1.5 mg/dl, transaminases < twice the upper limit of normal), and renal (serum creatinine <1.5 mg/dl) function. Brain metastases were allowed provided that they were irradiated, with clinical and radiologic improvement. Patients with malnutrition, active infection, massive liver metastases covering more than 50% of the liver surface, or a second primary tumour other than skin squamous carcinoma or in situ cervical carcinoma, were excluded Table 1 . Patient characteristics. from the study All patients gave written informed consent to participate in the study.
Characteristic Number of patients (%)
Treatment
CPT-11 was given at the dose of 100 mg/m 2 on day 1 and 110mg/m 2 on day 8 over a 60-min i.v. infusion. Cisplatin was administered at the dose of 80 mg/m 2 on day 8, over a 90-min i.v infusion after appropriate hydration, following CPT-11 administration. Treatment was repeated every three weeks if the absolute granulocyte count (AGC) was > 1500/dl and platelets > 100.000/dl, and all non-hematologic toxicities had been resolved. For the control of delayed-onset diarrhea, patients were adviced to take 2 mg of loperamide every four hours, as previously reported [7] .
In case of a complete response, patients received three additional cycles of chemotherapy after the criteria of complete response were first met. Patients with partial response were treated until disease progression or for a maximum of nine cycles, whilst patients with stable disease received a maximum of six cycles. Patients experiencing progressive disease during the treatment were withdrawn from the study.
Patient evaluation
Baseline evaluations included a complete medical history, physical examination, chest X-rays, full blood count (FBC) with differential and platelet count, blood chemistry, electrocardiograph (ECG), computed tomography (CT) scans of the chest, abdomen, and pelvis, while whole brain CT scans were performed when clinically indicated. FBCs with differential and platelets count were performed twice weekly or daily in patients with severe myelosuppression; whole blood chemistry and physical examination were performed every three weeks. Standard WHO criteria were used to evaluate response to treatment and toxicities.
Statistical analysis
The duration of response was calculated from the day of the first demonstration of response until disease progression; the time to tumor progression (TTP) was estimated from the study entry until the documented progression of the disease, and the overall survival was measured from the study entry until death. Median probability of survival and the median TTP were estimated by the method of Kaplan and Meier.
Results
Demographics
From March 1998 to August 1999, 31 patients with inoperable NSCLC were enrolled onto the study. Patient characteristics are shown in Table 1 .
Toxicity
A total of 110 chemotherapy cycles were administered and toxicity data were available from all patients and all cycles. Treatment was discontinued after the first cycle of treatment in three (10%) patients because of treatment refusal (1 patient), neurotoxicity grade 3 (1 patient), and diarrhea grade 3-4 (1 patient). Twenty-eight (90%) patients stopped the treatment after at least two cycles for the following reasons: progressive disease (19 patients), stable disease (2 patients), completion of six cycles of therapy (3 patients), personal reasons unrelated to treatment or disease (3 patients), and death due to disease progression (1 patient). Eight patients (26%) received six or more chemotherapy cycles. Dose reductions in both CPT-11 and CDDP were required in eight cycles (7%), and in all cases this was due to neutropenia (5 cycles) and/or grade 3-4 diarrhea (3 cycles). Thirty (27%) cycles were delayed at day 1 because of unresolved toxicity (n = 21) and late admissions (n = 9). Overall, the median interval between cycles was 22 days (range 21-28). The median CPT-11 administered dose was 63 mg/m 2 /week representing the 90% of the predicted protocol dose; the median cisplatin administered dose was 25 mg/m 2 /week representing the 92% of the predicted dose.
Hematologic toxicity
Grade 3-4 neutropenia was observed in 16 patients (52%) and in 2 of them this was complicated with fever requiring patient's hospitalization. The granulocyte nadir usually occurred between days 12 and 17 and the median time for recovery after grade 3-4 neutropenia was 5 days (range 3-8 days). There was no toxic death. Grade 1 and 2 anemia was observed in 15 (48%) and 13 (42%) patients, respectively. Grade 3 and 4 thrombocytopenia occurred in two (7%) patients, respectively.
Non-hematologic toxicities
Grade 3-4 diarrhea was seen in 10 (33%) patients and 3 of them required hospitalization. The onset of the first diarrheal episode was usually seen on day 12 (range 7-15) and in most cases recovery was seen within 3-4 days. All patients fully recovered within one week after administration of i.v. fluids and electrolytes. Acute cholinergic syndrome, directly attributed to CPT-11, was observed in two patients and both were treated with 0.5 mg atropine subcutaneously. Grade 2-3 nausea and vomiting were observed in 20 patients (59%), whilst grade 2 mucositis was seen in 2 (8%). Grade 2 fatigue was seen in 10 (33%) patients and grade 3 in 2 (7%), the last requiring treatment interruption. Grade 2 neurotoxicity was observed in one (3%) patient, and grade 3 in another one (3%).
Response to treatment
Twenty-eight patients were evaluable for response. Three other patients who stopped their treatment after the first chemotherapy cycle were considered as non-responders in an intention-to-treat analysis. Seven (23%) patients showed partial response, six (19%) stable disease, and eighteen (58%) progressive disease (95% confidence interval (95% CI): 8%-37%). Of seven responding patients, four had been previously treated with a docetaxelcarboplatin combination and three with a docetaxelgemcitabine combination. Five of the responders had failed front-line treatment. The median time off frontline treatment was 2 months (range 1-10 months) for the whole population and 1.5 month (range 1-6 months) for the responders. The median duration of response was 3 months (range 1-8.5) and the median time to tumor progression was 8 months (range 3-12). The median survival for the entire group was 8 months (range 2-17) and the probability of one-year survival was 22%. After a median follow-up period of 6 months (range 2-17), 13 (42%) patients are still alive.
Discussion
In a previous phase I trial we demonstrated that in pretreated NSCLC patients, the maximum tolerated dose of the combination is CPT-11 100 mg/m 2 on day 1 and 110 mg/m 2 on day 8 and cisplatin 80 mg/m 2 on day 8 [7] . This schedule of administration was selected because in a pilot study, when cisplatin was administered on day 1 together with CPT-11, the administration of CPT-11 on day 8 was frequently omitted because of unresolved toxicities.
In the present phase II study, the main hematologic toxicity of the CPT-11-cisplatin combination was neutropenia. Grade 3-4 neutropenia occurred in 16 (52%) patients and in two of them this was febrile, requiring the patient's hospitalization. Severe anemia was infrequent, while thrombocytopenia grade 3 and 4 occurred in two (7%) patients, respectively. Delayed-onset diarrhea was the main non-hematologic toxicity of the regimen. Its occurrence was unpredictable, with varying severity from one cycle to the next. In three out of ten patients complicated with grade 3-4 diarrhea, patient hospitalization was required for hydration and electrolyte replacement. Diarrhea was generally well-controlled with loperamide treatment, except in cases complicated with concurrent febrile neutropenia which prolonged the duration and the severity of the episodes. Grade 2 fatigue was observed in 10 patients and grade 3 in 2, the last requiring treatment interruption. This toxicity seems to be cumulative since the majority of the patients experienced some degree of fatigue after the third treatment cycle. The other non-hematologic toxicities were very mild.
The 23% objective tumor responses observed, accompanied with a median survival of 8 months are in keeping to that reported in previous studies involving patients who receive second line treatment for advanced NSCLC giving an indication as to the role of second-line chemotherapy in the treatment of relapsing or refractory NSCLC [8] . However, small differences in response rates and survival between studies may de due to differences in patient's selection (e.g., PS, disease stage, type of relapse, etc.). Remarkably, in the present study, five partial responses were seen in patients who had failed the previous docetaxel-based front-line chemotherapy regimen. This indicates that there is no complete crossresistance between these two drug combinations and response to second-line CPT-11-cisplatin regimen may be independent of the response to docetaxel-based front-line chemotherapy. Defining subgroups of patients according to clinical or biological tumor parameters with a higher probability to respond to second-line treatment, will be of interest.
In conclusion, the present trial has demonstrated that the CPT-11-cisplatin combination has manageable toxicity and interesting activity as treatment of patients with advanced NSCLC, who failed first-line docetaxelbased chemotherapy. Given these data and pending the results of larger randomized trials, a reasonable practice at this time would be to offer a chance of second-line chemotherapy to good performance status NSCLC patients, who have failed front-line treatment.
